<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mochamad Yusuf Alsagaff</style></author><author><style face="normal" font="default" size="100%">Melly Susanti</style></author><author><style face="normal" font="default" size="100%">Mochammad Thaha</style></author><author><style face="normal" font="default" size="100%">Christian Jonatan</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Inotropes in Chronic Beta-Blocker Therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Beta-blocker</style></keyword><keyword><style  face="normal" font="default" size="100%">Decompensated heart failure</style></keyword><keyword><style  face="normal" font="default" size="100%">Inotropes</style></keyword><keyword><style  face="normal" font="default" size="100%">Severe sepsis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">May 2021</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><pages><style face="normal" font="default" size="100%">828-834</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;The increasing rate of cardiovascular disorders contributes to rising hospitalized patients receive chronic oral beta-blocker therapy. Beta-blockers remain one of the fundamental therapy for chronic heart failure. Still, their role in decompensated heart failure and severe sepsis during hospitalization is often debated and inconsistent in clinical practice. In recent years, evidence of the efficacy and clinical outcomes of beta-blockers in acute heart failure (AHF) have accumulated. Clinical research indicates that chronic beta-blockade withdrawals should be prevented, or as soon as hemodynamic stabilization and euvolemic condition are reached, it should be reinstituted. As a subset of AHF patients with low cardiac output required inotropes, the choice of proper agent is fundamental. Different inotropic agents such as inhibitors of the phosphodiesterase, levosimendan, and dobutamine also their associations with beta-blockers are discussed.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Review Article</style></work-type><section><style face="normal" font="default" size="100%">828</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Mochamad Yusuf Alsagaff&lt;sup&gt;1,&lt;/sup&gt;*, Melly Susanti&lt;sup&gt;1&lt;/sup&gt;, Mochammad Thaha&lt;sup&gt;2&lt;/sup&gt;, Christian Jonatan&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Prof Moestopo Street 6-8, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Prof Moestopo Street 6-8, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>